BCAX (Bicara Therapeutics) Insider Ownership: 1.23 % (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $27.56
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Insider Ownership?

Bicara Therapeutics BCAX -1.83% 12 Insider Ownership is 1.23 % as of Jul. 17, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bicara Therapeutics's insider ownership is 1.23%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bicara Therapeutics's Institutional Ownership is 111.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bicara Therapeutics's Float Percentage Of Total Shares Outstanding is 71.59%.

Bicara Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Insider Ownership Chart

Bicara Therapeutics Historical Data

The historical data trend for Bicara Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 1.40 1.40 1.40 1.40 1.36 1.35 1.47 1.24 1.23 1.23
BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.23 % mean?
Bicara Therapeutics (BCAX) has a Insider Ownership of 1.23 % as of Jul. 17, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Insider Ownership too high?
Bicara Therapeutics' current Insider Ownership is 1.23 %. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Insider Ownership compare to ZYME and SRPT?
Bicara Therapeutics' Insider Ownership of 1.23 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Insider Ownership is 1.23 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Insider Ownership of 1.23 %. The current Insider Ownership is 1.23 %. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Insider Ownership is 1.23 % as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.56
Price